Population-based study of long-term functional outcomes after prostate cancer treatment

Sigrid Carlsson, Linda Drevin, Stacy Loeb, Anders Widmark, Ingela Franck Lissbrant, David Robinson, Eva Johansson, Pär Stattin, Per Fransson, Sigrid Carlsson, Linda Drevin, Stacy Loeb, Anders Widmark, Ingela Franck Lissbrant, David Robinson, Eva Johansson, Pär Stattin, Per Fransson

Abstract

Objective: To evaluate long-term urinary, sexual and bowel functional outcomes after prostate cancer treatment at a median (interquartile range) follow-up of 12 (11-13) years.

Patients and methods: In this nationwide, population-based study, we identified 6 003 men diagnosed with localized prostate cancer (clinical local stage T1-2, any Gleason score, prostate-specific antigen <20 ng/mL, NX or N0, MX or M0) between 1997 and 2002 from the National Prostate Cancer Register, Sweden. The men were aged ≤70 years at diagnosis. A control group of 1 000 men without prostate cancer were also selected, matched for age and county of residence. Functional outcomes were evaluated with a validated self-reported questionnaire.

Results: Responses were obtained from 3 937/6 003 cases (66%) and 459/1 000 (46%) controls. At 12 years after diagnosis and at a median age of 75 years, the proportion of cases with adverse symptoms was 87% for erectile dysfunction/sexual inactivity, 20% for urinary incontinence and 14% for bowel disturbances. The corresponding proportions for controls were 62, 6 and 7%, respectively. Men with prostate cancer, except those on surveillance, had an increased risk of erectile dysfunction compared with the men in the control group. Radical prostatectomy was associated with an increased risk of urinary incontinence (odds ratio [OR] 1.89, 95% confidence interval [CI] 1.36-2.62) and radiotherapy increased the risk of bowel dysfunction (OR 2.46, 95% CI 1.73-3.49) compared with men in the control group. Multi-modal treatment, in particular treatment including androgen deprivation therapy (ADT), was associated with the highest risk of adverse effects; for instance, radical prostatectomy followed by radiotherapy and ADT was associated with an OR of 3.74 (95% CI 1.76-7.95) for erectile dysfunction and an OR of 3.22 (95% CI 1.93-5.37) for urinary incontinence.

Conclusion: The proportion of men who experienced a long-term impact on functional outcomes after prostate cancer treatment was substantial.

Keywords: erectile dysfunction; prostate cancer; prostatic neoplasms/therapy; quality of life; urinary incontinence.

Conflict of interest statement

None declared.

© 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Flow chart of study participants.
Figure 2
Figure 2
Odds ratios and 95% confidence intervals for the risk of adverse functional outcomes by treatment compared to controls and adjusted for age.

References

    1. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med 2008; 358: 1250–61
    1. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117–23
    1. Prostate Cancer – National quality report, 2012 . Regional cancer centre, Uppsala Örebro, Sweden. Available at: . Accessed January 2015
    1. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 2013; 190: 1742–9
    1. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow‐up study. J Natl Cancer Inst 2010; 102: 950–8
    1. Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer‐specific mortality after radical prostatectomy for patients treated in the prostate‐specific antigen era. J Clin Oncol 2009; 27: 4300–5
    1. Resnick MJ, Koyama T, Fan KH et al. Long‐term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368: 436–45
    1. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long‐term health‐related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol 2014. [Epub ahead of print]. doi: 10.1016/j.eururo.2014.08.074
    1. Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J; National Prostate Cancer Register . Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008; 180: 2423–9
    1. Van Hemelrijck M, Wigertz A, Sandin F et al. NPCR and PCBaSe Sweden. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data base Sweden 2.0. Int J Epidemiol 2013; 42: 956–67
    1. Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy‐induced side effects. Support Care Cancer 2001; 9: 187–98
    1. Reidunsdatter RJ, Lund JA, Fransson P, Widmark A, Fossa SD, Kaasa S. Validation of the intestinal part of the prostate cancer questionnaire “QUFW94”: psychometric properties, responsiveness, and content validity. Int J Radiat Oncol Biol Phys 2010; 77: 793–804
    1. Hamoen EH, De Rooij M, Witjes JA, Barentsz JO, Rovers MM. Measuring health‐related quality of life in men with prostate cancer: a systematic review of the most used questionnaires and their validity. Urol Oncol 2014; 33: 69.e19–28
    1. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5‐item version of the International Index of Erectile Function (IIEF‐5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–26
    1. Barry MJ, Fowler FJ Jr, O Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–57
    1. Carlsson S, Aus G, Bergdahl S et al. The excess burden of side‐effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population‐based prostate cancer screening trial. Eur J Cancer 2011; 47: 545–53
    1. van Buuren S. Flexible Imputation of Missing Data. Boca Raton, FL: Chapman & Hall/CRC, 2012. ISBN 9781439868249
    1. Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol 2009; 181: 462–71
    1. Johansson E, Steineck G, Holmberg L et al. Long‐term quality‐of‐life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group‐4 randomised trial. Lancet Oncol 2011; 12: 891–9
    1. NIH Consensus Conference . Impotence. NIH consensus development panel on impotence. JAMA 1993; 270: 83
    1. Wu AK, Cooperberg MR, Sadetsky N et al. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol 2008; 180: 2415–22
    1. Penson DF, McLerran D, Feng Z et al. 5‐year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005; 173: 1701–5
    1. Prabhu V, Taksler GB, Sivarajan G, Laze J, Makarov DV, Lepor H. Radical prostatectomy improves and prevents age dependent progression of lower urinary tract symptoms. J Urol 2014; 191: 412–7
    1. Anderson CB, Penson DF, Ni S, Makarov DV, Barocas DA. Centralization of radical prostatectomy in the United States. J Urol 2013; 189: 500–6

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다